Compare Incyte Corporation (INCY) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Meta Platforms Inc — how do they compare? Incyte Corporation trades at $118.08 (market cap $23.11B), while Meta Platforms Inc trades at $649.77 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 71× Incyte Corporation's market cap, and Meta Platforms Inc pays a 0.33% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | META | |
|---|---|---|
Market Cap | $23.11B | $1.64T |
Sector | Health | Media |
52-Week High | $118.52 | $790.00 |
52-Week Low | $67.38 | $525.72 |
Enterprise Value | $19.13B | $1.65T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
META trades at $647.42, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 23.49, net income margin of 32.84%, and consistent earnings beats. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with analyst consensus at Buy (79.37%) and a $817.32 price target, supported by robust revenue growth and AI investments. Key risks include regulatory lawsuits and high capital expenditures. The stock presents a growth opportunity but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
